Address correspondence to Dr Amanda C. Peltier, Vanderbilt University Medical Center, A-0118 Medical Center North, Nashville, TN 37232, Amanda.firstname.lastname@example.org.
RELATIONSHIP DISCLOSURE: Dr Peltier serves as secretary for the International Diabetes Neuropathy Consortium, on the board of directors of the American Autonomic Society, and on advisory boards for Akcea Therapeutics; Alnylam Pharmaceuticals, Inc; and CSL Behring. Dr Peltier has received personal compensation for speaking engagements from Akcea Therapeutics and CSL Behring and research/grant support from Akcea Therapeutics; CSL Behring; and the National Institute of Neurological Disorders and Stroke NeuroNEXT. Dr Wood reports no disclosure.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Wood and Peltier discuss the unlabeled/investigational use of α-lipoic acid, amitriptyline, cannabidiol oil, carbamazepine, nortriptyline, oxcarbazepine, spinal cord stimulators, valproic acid, and venlafaxine for the treatment of neuropathic pain in polyneuropathy.